This review focuses primarily on the recently identified roles of YKL-40 in facilitating both angiogenesis and VM in GBM, with a focus on current therapeutic limitations evident in the treatment of patients with conventional anti-angiogenic drugs. Here, CHI3L1 is linked to glioblastoma.